Aravive, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARAV research report →
Range $0.25 – $0.25
Price Chart
About the company
Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway.
- CEO
- Fredric N. Eshelman
- IPO
- 2014
- Employees
- 23
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on ARAV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.95M
- P/E
- -0.02
- PEG
- -0.00
- P/S
- 0.32
- P/B
- 0.14
- EV/EBITDA
- 0.63
- Div Yield
- 0.00%
- Gross Margin
- -632.60%
- Op Margin
- -775.28%
- Net Margin
- -885.64%
- ROE
- -306.06%
- ROIC
- -161.69%
Latest fiscal year · YoY change
- Revenue
- $9.14M+22.8%
- Gross Profit
- $-57,801,000-92.0%
- Op Income
- $-70,837,000
- Net Income
- $-80,921,000-112.2%
- EPS
- $-2.22-16.8%
- OCF Growth
- -102.3%
- FCF Growth
- -102.3%
- 52W High
- $2.46
- 52W Low
- $0.04
- 50D MA
- $0.10
- 200D MA
- $0.59
- Beta
- 2.19
- RSI (14)
- 21
- Avg Volume
- 2.24M
No earnings-call transcripts are available for ARAV yet.
- Free Float
- 61.3%
- Shares Outstanding
- 73.56M
- Float Shares
- 45.08M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ARAV, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Bob GibbsHouse · oH07 | Sell | Dec 28, 18 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Qs Investors, LLC | 37.80K | ▲ 37.80K |
Held by 17 ETFs
Biggest fund positions in ARAV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 10, 23 | Petrini Maria Carolina | other | 400,000 |
| Apr 10, 23 | Petrini Maria Carolina | other | 0 |
| Feb 1, 23 | McIntyre Gail Frances | other | 700,000 |
| Feb 1, 23 | Geller Robert B. | other | 400,000 |
| Feb 1, 23 | HOWARD RUDY | other | 400,000 |
| Feb 1, 23 | Dove Leonard Scott | other | 400,000 |
| Oct 24, 22 | Ho Peter Tai-Ching | other | 54,353 |
| Oct 24, 22 | Zhang Eric | other | 271,769 |
| Oct 24, 22 | Zhang Eric | other | 271,768 |
| Oct 24, 22 | Giaccia Amato | other | 271,768 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ARAV coverage
Recent articles, reports, and earnings notes.
No research on ARAV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARAV report →Kratos' Aegis Readiness Assessment Vehicle Type B (ARAV-B) Medium-Range Ballistic Missile Target Successfully Engaged, Intercepted by U.S. Guided Missile Destroyers USS Bulkeley (DDG-84) and USS Thomas Hudner (DDG-116) Using Standard Missile 3 (SM-3)
globenewswire.com · Jun 12
Why Is Aravive (ARAV) Stock Down 52% Today?
investorplace.com · Jan 18
Aravive stock slumps on Nasdaq delisting plan, dissolution
proactiveinvestors.com · Jan 18
Aravive, Inc. to Delist from The Nasdaq Stock Market
globenewswire.com · Jan 17
Penny Stocks To Buy? Watch These 3 Under $5 Before Next Week
pennystocks.com · Oct 20
Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?
zacks.com · Oct 13
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 21
Why Is Aravive (ARAV) Stock Down 58% Today?
investorplace.com · Aug 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.